On one hand, it possesses tumor preventive properties, whereas on the other hand, it can promote tumor progression.15Mutations inNFE2L2/KEAP1have been linked to increased tumor mutational burden (TMB) and PD-L1 expression, resulting in improved clinical responses to immunotherapy and favorable patient outcomes.16Additionally, lung adenocarcinoma patients with co-occurring mutations inNFE2L2andKEAP1have shown poorer survival outcomes compared with those with a single mutation in either gene.17 The gene discussed is CD274; the disease is neoplasm.